Value Proposition: This invention uses a novel gene therapy that blocks the axon degeneration typical of neurodegenerative diseases.
Technology Description
Researchers at Washington University in St. Louis have developed a new strategy for treatment of neurodegenerative diseases with axonopathy. Axon loss is a central element of many types of neurodegenerative diseases including but not limited to peripheral neuropathy, glaucoma, traumatic brain injury, ALS, Parkinson’s Disease, MS, and Alzheimer’s Disease. SARM1 is an NAD+ cleaving enzyme that is the central executioner of the axon degeneration pathway. Currently, there is no practical method to inhibit SARM1 in patients.
This strategy uses a potent SARM1 dominant negative gene therapy, that blocks SARM1 activity and prevents axon degeneration, to treat neurodegenerative diseases in which axon degeneration is a major component of disease symptomatology.
Stage of Research
The research team has demonstrated that SARM1 dominant negatives K193R, H685A, and combined K193/H685A have the most potent effect in blocking axon degeneration in an in vitro model of axon degeneration in DRG neurons.
Applications
- Treatment of neurodegenerative diseases
Key Advantages
- Stops axon degeneration typical of neurodegenerative diseases
Patents:
- Issued Patent, JP73679882
- Additional application pending
Related Web Links – Aaron DiAntonio Profile; DiAntonio Lab
